A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Inclusion Criteria

• Male and female participants
• 18 years and older
• Histological or cytological confirmation of metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma
• Participants must have received and have progressed, or are refractory to standard regimens
• Participants must have at least one lesion amenable to biospy

Exclusion Criteria

• Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
• Previous immunotherapy
• Concurrent or prior use of immunosuppressive medication with 14 days
• Active or prior documented autoimmune or inflammatory disease within 3 years with some exceptions